CIBC Asset Management Inc Has $13.35 Million Position in Becton, Dickinson and Company (NYSE:BDX)

CIBC Asset Management Inc boosted its position in Becton, Dickinson and Company (NYSE:BDX) by 3.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 58,871 shares of the medical instruments supplier’s stock after purchasing an additional 1,948 shares during the period. CIBC Asset Management Inc’s holdings in Becton, Dickinson and Company were worth $13,348,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Sierra Ocean LLC acquired a new position in Becton, Dickinson and Company in the 4th quarter worth about $29,000. Ashton Thomas Securities LLC acquired a new stake in shares of Becton, Dickinson and Company in the third quarter valued at about $33,000. Tompkins Financial Corp increased its stake in shares of Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 46 shares during the period. Kennebec Savings Bank acquired a new stake in shares of Becton, Dickinson and Company in the third quarter valued at about $46,000. Finally, Versant Capital Management Inc increased its stake in shares of Becton, Dickinson and Company by 54.1% in the fourth quarter. Versant Capital Management Inc now owns 208 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 73 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 2,838 shares of the stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $223.33, for a total value of $633,810.54. Following the transaction, the executive vice president now owns 6,141 shares in the company, valued at approximately $1,371,469.53. This represents a 31.61 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Roland Goette sold 4,483 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $221.01, for a total value of $990,787.83. Following the completion of the transaction, the executive vice president now owns 24,345 shares in the company, valued at $5,380,488.45. This represents a 15.55 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,544 shares of company stock worth $2,370,309. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.1 %

Shares of Becton, Dickinson and Company stock opened at $225.11 on Wednesday. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.74. The stock’s 50-day moving average is $232.64 and its 200 day moving average is $233.54. The firm has a market cap of $64.64 billion, a price-to-earnings ratio of 37.39, a PEG ratio of 1.65 and a beta of 0.40.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Equities research analysts anticipate that Becton, Dickinson and Company will post 14.41 EPS for the current year.

Becton, Dickinson and Company declared that its board has authorized a share buyback plan on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 outstanding shares. This repurchase authorization authorizes the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a $1.04 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 annualized dividend and a yield of 1.85%. Becton, Dickinson and Company’s payout ratio is currently 69.10%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on BDX shares. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, February 12th. Piper Sandler increased their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. Finally, Barclays increased their price target on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Buy” and a consensus target price of $278.29.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.